150 related articles for article (PubMed ID: 34114978)
1. Effect of aprepitant on kynurenine to tryptophan ratio in cART treated and cART naïve adults living with HIV.
Spitsin S; Pappa V; Kinder A; Evans DL; Rappaport J; Douglas SD
Medicine (Baltimore); 2021 Jun; 100(23):e25313. PubMed ID: 34114978
[TBL] [Abstract][Full Text] [Related]
2. Antiinflammatory effects of aprepitant coadministration with cART regimen containing ritonavir in HIV-infected adults.
Spitsin S; Tebas P; Barrett JS; Pappa V; Kim D; Taylor D; Evans DL; Douglas SD
JCI Insight; 2017 Oct; 2(19):. PubMed ID: 28978797
[TBL] [Abstract][Full Text] [Related]
3. Increased Tryptophan Catabolism Is Associated With Increased Frequency of CD161+Tc17/MAIT Cells and Lower CD4+ T-Cell Count in HIV-1 Infected Patients on cART After 2 Years of Follow-Up.
Gaardbo JC; Trøsied M; Stiksrud B; Midttun Ø; Ueland PM; Ullum H; Nielsen SD
J Acquir Immune Defic Syndr; 2015 Nov; 70(3):228-35. PubMed ID: 26470032
[TBL] [Abstract][Full Text] [Related]
4. Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults.
Tebas P; Spitsin S; Barrett JS; Tuluc F; Elci O; Korelitz JJ; Wagner W; Winters A; Kim D; Catalano R; Evans DL; Douglas SD
AIDS; 2015 May; 29(8):931-9. PubMed ID: 25915168
[TBL] [Abstract][Full Text] [Related]
5. A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults.
Tebas P; Tuluc F; Barrett JS; Wagner W; Kim D; Zhao H; Gonin R; Korelitz J; Douglas SD
PLoS One; 2011; 6(9):e24180. PubMed ID: 21931661
[TBL] [Abstract][Full Text] [Related]
6. Tryptophan catabolism and immune activation in primary and chronic HIV infection.
Gelpi M; Hartling HJ; Ueland PM; Ullum H; Trøseid M; Nielsen SD
BMC Infect Dis; 2017 May; 17(1):349. PubMed ID: 28511640
[TBL] [Abstract][Full Text] [Related]
7. The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy.
Byakwaga H; Boum Y; Huang Y; Muzoora C; Kembabazi A; Weiser SD; Bennett J; Cao H; Haberer JE; Deeks SG; Bangsberg DR; McCune JM; Martin JN; Hunt PW
J Infect Dis; 2014 Aug; 210(3):383-91. PubMed ID: 24585899
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV.
Barrett JS; Spitsin S; Moorthy G; Barrett K; Baker K; Lackner A; Tulic F; Winters A; Evans DL; Douglas SD
J Transl Med; 2016 May; 14(1):148. PubMed ID: 27230663
[TBL] [Abstract][Full Text] [Related]
9. Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.
Bussmann H; Wester CW; Thomas A; Novitsky V; Okezie R; Muzenda T; Gaolathe T; Ndwapi N; Mawoko N; Widenfelt E; Moyo S; Musonda R; Mine M; Makhema J; Moffat H; Essex M; Degruttola V; Marlink RG
J Acquir Immune Defic Syndr; 2009 May; 51(1):37-46. PubMed ID: 19282782
[TBL] [Abstract][Full Text] [Related]
10. Aprepitant in the Treatment of Subacute Sclerosing Panencephalitis: A Randomized, Double-Blind, Placebo-Controlled Study.
Oncel I; Sancar M; Konuskan B; Arioz F; Tezcan S; Arman-Kandirmaz E; Parlak S; Gumeler E; Anlar B
Pediatr Neurol; 2020 Sep; 110():59-63. PubMed ID: 32718528
[TBL] [Abstract][Full Text] [Related]
11. Modeling and simulation approach to support dosing and study design requirements for treating HIV-related neuropsychiatric disease with the NK1-R antagonist aprepitant.
Barrett JS; Bajaj G; McGuire J; Wu D; Spitsin S; Moorthy G; Zhao X; Tebas P; Evans DL; Douglas SD
Curr HIV Res; 2014; 12(2):121-31. PubMed ID: 24862330
[TBL] [Abstract][Full Text] [Related]
12. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F
HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336
[TBL] [Abstract][Full Text] [Related]
13. Tryptophan metabolism and its relationship with central nervous system toxicity in people living with HIV switching from efavirenz to dolutegravir.
Keegan MR; Winston A; Higgs C; Fuchs D; Boasso A; Nelson M
J Neurovirol; 2019 Feb; 25(1):85-90. PubMed ID: 30478800
[TBL] [Abstract][Full Text] [Related]
14. Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals.
Manak MM; Moshkoff DA; Nguyen LT; Meshki J; Tebas P; Tuluc F; Douglas SD
AIDS; 2010 Nov; 24(18):2789-96. PubMed ID: 20975512
[TBL] [Abstract][Full Text] [Related]
15. Effective antiretroviral therapy reduces degradation of tryptophan in patients with HIV-1 infection.
Zangerle R; Widner B; Quirchmair G; Neurauter G; Sarcletti M; Fuchs D
Clin Immunol; 2002 Sep; 104(3):242-7. PubMed ID: 12217334
[TBL] [Abstract][Full Text] [Related]
16. [GESIDA/National AIDS Plan: Consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (Updated January 2015)].
Panel de expertos de GeSIDA y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2015 Oct; 33(8):543.e1-43. PubMed ID: 25959461
[TBL] [Abstract][Full Text] [Related]
17. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team.
Nachman SA; Stanley K; Yogev R; Pelton S; Wiznia A; Lee S; Mofenson L; Fiscus S; Rathore M; Jimenez E; Borkowsky W; Pitt J; Smith ME; Wells B; McIntosh K
JAMA; 2000 Jan; 283(4):492-8. PubMed ID: 10659875
[TBL] [Abstract][Full Text] [Related]
18. Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults.
Young B; Fischl MA; Wilson HM; Finn TS; Jensen EH; DiNubile MJ; Zeldin RK
J Acquir Immune Defic Syndr; 2002 Dec; 31(5):478-82. PubMed ID: 12473835
[TBL] [Abstract][Full Text] [Related]
19. Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial.
Nakanjako D; Ssinabulya I; Nabatanzi R; Bayigga L; Kiragga A; Joloba M; Kaleebu P; Kambugu AD; Kamya MR; Sekaly R; Elliott A; Mayanja-Kizza H
Trop Med Int Health; 2015 Mar; 20(3):380-90. PubMed ID: 25441397
[TBL] [Abstract][Full Text] [Related]
20. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
